Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities). $35.0M funded, with total senior secured borrowing capacity up to $150.0M across five tranches.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $35.0M funded, with total senior secured borrowing capacity up to $150.0M across five tranches
- Floating interest rate: greater of prime rate or 6.75%, plus 2.40%, creating substantial rate exposure
- Interest-only through April 1, 2029, extendable to April 1, 2030 or October 1, 2030 upon milestone achievements
- Debt matures October 1, 2030, extendable to October 1, 2031 after the Tranche 2 Milestone
- First-priority liens cover substantially all assets, including intellectual property, while warrants cover up to 1,755,853 shares at $2.99 per share
Item 3.02 · Unregistered Sales of Equity Securities
- Warrants issued to lenders in a private placement under Securities Act Section 4(a)(2)
- Underlying common shares unregistered, creating potential future dilution if warrants are exercised
- Lenders qualified as accredited investors and acquired warrants for investment, limiting immediate public distribution concerns
Item 7.01 · Regulation FD Disclosure
- Loan Agreement with Hercules announced, indicating new financing for Rocket Pharmaceuticals
- Investor presentation updates the Danon Disease Program, relevant to clinical and corporate outlook
- Corporate webinar held October 6, 2026, with materials furnished as Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.1
- Credit facility up to $150 million with Hercules Capital, adding funding flexibility for RP-A501’s pivotal Phase 2 Danon study
- $35 million funded at closing, with potential additional draws of $35 million, $30 million upon a Danon milestone, and $50 million subject to approval
- 30-month interest-only period and 48-month maturity, plus warrants that may dilute common shareholders
- Cash, equivalents and investments of $283.7 million as of June 30, 2026, plus initial proceeds expected to fund operations into Q3 2028
- Additional borrowing could extend runway into 2029, contingent on milestones, borrowing conditions, covenants and future operating expenditures
Item EX-99.2 · Exhibit EX-99.2
- RP-A501 Phase 1 showed durable cardiac benefit up to 7 years, with 100% overall survival and transplant-free survival median not reached
- Pivotal Phase 2 Cohort 4 uses recalibrated dose and revised immunomodulation after serious adverse events in discontinued Cohort 3
- Cohort 4 safety improved: 1 of 3 patients had a serious Grade ≥3 event, with no thrombotic microangiopathy or capillary leak
- FDA agreement supports completing the 12-patient pivotal study for potential accelerated approval and priority review voucher eligibility
- Key catalysts: dosing completion targeted mid-2027, topline efficacy data mid-2028, BLA filing late-2028
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.